Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENSBiotechnology
-$0.02 today
- Market cap
- $141.41M
- Beta
- 2.08
- P/E (TTM)
- -25.1
- EPS (TTM)
- -$0.06
Volume 0.07M
Average 0.10M
MENS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Jyong Biotech Ltd. Ordinary SharesNASDAQ: MENS
EBITDA · Q4 FY2025 · quarter ended Dec 2025
EBITDA remains negative
Q4 FY2025 EBITDA was -$1.79M, compared with -$523.5 a year earlier. Trailing-twelve-month EBITDA was -$1.94K.
Context
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly EBITDA holds near -$1.79M or moves back toward the trailing-twelve-month quarterly average of -$484.
Sources:Income StatementText generated from reported figures; not investment advice.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (2.51M) USD
- Year-over-year change
- -34.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.51M) | -34.5% |
| FY2024 | 2024-12-31 | (1.86M) | +47.0% |
| FY2023 | 2023-12-31 | (3.52M) | +38.8% |
| FY2022 | 2022-12-31 | (5.74M) | -77.2% |
| FY2021 | 2021-12-31 | (3.24M) | — |
EBITDA vs competitors
How MENS compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $99.55M USD | +154.3% | — | 7.3% | |
| LTM Dec 2024 | -$1.94K USD | — | — | — | |
| LTM Sep 2026 | -$106.58M USD | -372.0% | — | 16.4% | |
| LTM Jun 2026 | -$185.22M USD | -36.6% | — | — | |
| LTM Sep 2026 | -$233.76M USD | -54.9% | — | 3791.2% | |
| LTM Mar 2026 | -$260.55M USD | -24.8% | — | — | |
| LTM Jun 2026 | -$291.3M USD | -23.0% | — | — | |
| LTM Sep 2026 | -$434.65M USD | -30.9% | — | — | |
| LTM Jun 2026 | -$495.35M USD | -20.6% | — | — | |
| LTM Mar 2026 | -$503.35M USD | -11.9% | — | 75.2% | |
AAPGAscentage Pharma Group International | FY2025 | -CN¥1.1B CNY | -360.8% | — | 196.1% |
| Peer median (excluding MENS) | — | -27.9% | — | 75.2% | |
Competitors are the stored peer set for MENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 121K | 122K | 127K | 120K | 100K |
| Gross Profit | (121K) | (122K) | (127K) | (120K) | (100K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 1.56M | 1.29M | 1.07M | 927K | 731K |
| Selling, General & Admin | 845K | 1.54M | 1.73M | 1.13M | 1.78M |
| Operating Expenses | 2.4M | 2.83M | 2.8M | 2.06M | 2.51M |
| Depreciation & Amortization | 122K | 123K | 127K | 120K | 100K |
| EBITDA | (3.24M) | (5.74M) | (3.52M) | (1.86M) | (2.51M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (2.4M) | (2.83M) | (2.8M) | (2.06M) | (2.61M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 6K | 5K | 56K | 7K | 610K |
| Interest Expense | 835K | 765K | 757K | 1.04M | 2.54M |
| Other Income / Expenses | (1.79M) | (3.8M) | (1.6M) | (963K) | (2.06M) |
| Income Before Tax | (4.2M) | (6.63M) | (4.4M) | (3.02M) | (4.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (4.2M) | (6.63M) | (4.4M) | (3.02M) | (4.67M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.06) | (0.09) | (0.06) | (0.04) | (0.06) |
| EPS (Diluted) | (0.06) | (0.09) | (0.06) | (0.04) | (0.06) |
| Weighted Avg Shares | 76.03M | 76.03M | 76.03M | 76.03M | 73.01M |
| Weighted Avg Shares (Diluted) | 76.03M | 76.03M | 76.03M | 76.03M | 73.01M |
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
Intrinsic Alpha fair value
Locked
Current Price
$1.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.